Seroreactvity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease

Z. Barta, I. Csípő, Gábor G. Szabó, G. Szegedi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Aim: To explore whether there was anti-Saccharomyces cerevisiae antibodies (ASCA) positivity in our patients with biopsy-confirmed celiac disease. Methods: A cohort of patients with inflammatory bowel diseases (42 patients with Crohn's disease and 10 patients with ulcerative colitis) and gluten sensitive enteropathy (16 patients) from Debrecen, Hungary were enrolled in the study. The diagnosis was made using the formally accepted criteria. Perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA), antiendomysium antibodies (EMA), antigliadin antibodies (AGA) and anti human tissue transglutaminase antibodies (tTGA) were investigated. Results: The results showed that ASCA positivity occurred not only in Crohn's disease but also in Celiac disease and in these cases both the IgG and IgA type antibodies were proved. Conclusion: It is conceivable that ASCA positivity correlates with the (auto-) immune inflammation of small intestines and it is a specific marker of Crohn's disease.

Original languageEnglish
Pages (from-to)2308-2312
Number of pages5
JournalWorld Journal of Gastroenterology
Volume9
Issue number10
Publication statusPublished - Oct 2003

Fingerprint

Celiac Disease
Crohn Disease
Saccharomyces cerevisiae
Antibodies
Antineutrophil Cytoplasmic Antibodies
Hungary
Ulcerative Colitis
Inflammatory Bowel Diseases
Immunoglobulin A
Small Intestine
Anti-Idiotypic Antibodies
Immunoglobulin G
Inflammation
Biopsy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Seroreactvity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease. / Barta, Z.; Csípő, I.; Szabó, Gábor G.; Szegedi, G.

In: World Journal of Gastroenterology, Vol. 9, No. 10, 10.2003, p. 2308-2312.

Research output: Contribution to journalArticle

@article{7d0833ef9d7c4fc8a35196d2b2818215,
title = "Seroreactvity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease",
abstract = "Aim: To explore whether there was anti-Saccharomyces cerevisiae antibodies (ASCA) positivity in our patients with biopsy-confirmed celiac disease. Methods: A cohort of patients with inflammatory bowel diseases (42 patients with Crohn's disease and 10 patients with ulcerative colitis) and gluten sensitive enteropathy (16 patients) from Debrecen, Hungary were enrolled in the study. The diagnosis was made using the formally accepted criteria. Perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA), antiendomysium antibodies (EMA), antigliadin antibodies (AGA) and anti human tissue transglutaminase antibodies (tTGA) were investigated. Results: The results showed that ASCA positivity occurred not only in Crohn's disease but also in Celiac disease and in these cases both the IgG and IgA type antibodies were proved. Conclusion: It is conceivable that ASCA positivity correlates with the (auto-) immune inflammation of small intestines and it is a specific marker of Crohn's disease.",
author = "Z. Barta and I. Cs{\'i}pő and Szab{\'o}, {G{\'a}bor G.} and G. Szegedi",
year = "2003",
month = "10",
language = "English",
volume = "9",
pages = "2308--2312",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "10",

}

TY - JOUR

T1 - Seroreactvity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease

AU - Barta, Z.

AU - Csípő, I.

AU - Szabó, Gábor G.

AU - Szegedi, G.

PY - 2003/10

Y1 - 2003/10

N2 - Aim: To explore whether there was anti-Saccharomyces cerevisiae antibodies (ASCA) positivity in our patients with biopsy-confirmed celiac disease. Methods: A cohort of patients with inflammatory bowel diseases (42 patients with Crohn's disease and 10 patients with ulcerative colitis) and gluten sensitive enteropathy (16 patients) from Debrecen, Hungary were enrolled in the study. The diagnosis was made using the formally accepted criteria. Perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA), antiendomysium antibodies (EMA), antigliadin antibodies (AGA) and anti human tissue transglutaminase antibodies (tTGA) were investigated. Results: The results showed that ASCA positivity occurred not only in Crohn's disease but also in Celiac disease and in these cases both the IgG and IgA type antibodies were proved. Conclusion: It is conceivable that ASCA positivity correlates with the (auto-) immune inflammation of small intestines and it is a specific marker of Crohn's disease.

AB - Aim: To explore whether there was anti-Saccharomyces cerevisiae antibodies (ASCA) positivity in our patients with biopsy-confirmed celiac disease. Methods: A cohort of patients with inflammatory bowel diseases (42 patients with Crohn's disease and 10 patients with ulcerative colitis) and gluten sensitive enteropathy (16 patients) from Debrecen, Hungary were enrolled in the study. The diagnosis was made using the formally accepted criteria. Perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA), antiendomysium antibodies (EMA), antigliadin antibodies (AGA) and anti human tissue transglutaminase antibodies (tTGA) were investigated. Results: The results showed that ASCA positivity occurred not only in Crohn's disease but also in Celiac disease and in these cases both the IgG and IgA type antibodies were proved. Conclusion: It is conceivable that ASCA positivity correlates with the (auto-) immune inflammation of small intestines and it is a specific marker of Crohn's disease.

UR - http://www.scopus.com/inward/record.url?scp=0142213417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142213417&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 2308

EP - 2312

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 10

ER -